Genitourinary cancer reasoning
Separate detection, tissue diagnosis, grading, anatomical stage and risk grouping. An elevated PSA is not equivalent to prostate cancer, and a biopsy result does not by itself establish the full extent of disease. MRI, sampling strategy, prior results, prostate volume and the clinical setting influence investigation. Gleason pattern combinations and corresponding Grade Groups contain different prognostic information even when the summed score is identical. PSA density is a ratio, not a universal decision rule that removes the need for individualized risk assessment.
Localized prostate cancer management ranges from active surveillance to definitive local treatment according to risk, life expectancy and informed preferences. Active surveillance is structured follow-up with criteria for reassessment, not abandonment of care. Metastatic hormone-sensitive and castration-resistant disease are distinct treatment settings. Prior therapy, symptoms, disease distribution and molecular findings can affect systemic choices. Do not transfer a medicine approved for one setting to every tumor carrying a familiar mutation.
Bladder cancer assessment depends on complete tumor characterization and the adequacy of sampling. Muscularis propria can be critical for establishing invasion, although specimen requirements differ in selected low-risk situations. Non-muscle-invasive disease is stratified by features such as grade, stage, carcinoma in situ and recurrence history. Intravesical treatment does not replace appropriate re-resection, staging or timely discussion of cystectomy in high-risk treatment-unresponsive disease. Current drug options evolve and require current specialist guidance.
Renal tumors differ in morphology, molecular pathways and clinical behavior. Clear-cell carcinoma is linked to the VHL pathway, while other subtypes have different characteristic findings. A small renal mass may permit nephron-sparing treatment in an appropriate person, but anatomy, comorbidity, competing risk and patient preference remain relevant. An imaging appearance suggestive of angiomyolipoma must still be interpreted carefully when features are atypical.
Testicular tumor markers help distinguish and monitor germ-cell tumor components. AFP elevation is inconsistent with a pure seminoma unless another explanation is established; mixed elements must be considered. Management after orchiectomy depends on the actual histology, marker trajectory, imaging and follow-up capability. Penile cancer similarly requires attention to primary-tumor and nodal risk. These chapters cover written cancer foundations and cannot establish complete contemporary Egyptian oncology pathways or competence in counseling a particular patient.